Today’s price, $64.88, sits above the range. 139.7% above the $27.07 the four methods put it at.
OVERVALUEDThe real sections, opened with your free account.
The 2 methods put TG Therapeutics’s fair value around $27.07 a share.
Latest report: July to September 2026 (quarter ended Sep 30, 2026), reported Nov 9, 2026 before the open.
Expectations are analysts’ averages as of Nov 8, 2026, before the report.
From the company's quarterly statements through Sep 30, 2026.
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million
From the earnings release filed Nov 9, 2026.
The full read in the IV Calculator adds what the filing said that the headlines skipped, margins and cash for the quarter, how each part of the business did, and how TGTX moved after its last eight reports.
See TGTX’s full earnings read, free →